3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
Dermatologic
2
Other hematologic neoplasm
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Sarcoma
2
Recurrence
2
Melanoma
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Merkel Cell
1
Interventions
Cyclophosphamide
39
Peripheral Blood Stem Cell Transplantation
32
fludarabine phosphate
30
Busulfan
26
Filgrastim
24
Cyclosporine
24
Mycophenolic Acid
22
Antilymphocyte Serum
22
Radiotherapy
20
Melphalan
16
Whole-Body Irradiation
15
Tacrolimus
14
Methylprednisolone
14
Methotrexate
13
Cord Blood Stem Cell Transplantation
12
Etoposide
10
sargramostim
5
Thiotepa
5
Temozolomide
5
Sirolimus
5
Rituximab
5
Bevacizumab
5
aldesleukin
4
Therapeutics
4
Granulocyte Colony-Stimulating Factor
4
Cytarabine
4
Carmustine
4
pembrolizumab
3
Vincristine
3
Topotecan
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recurrence
×
bempegaldesleukin
×
Sarcoma
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts
NCT03435640
2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2
Terminated
64 enrolled
22 charts